M H Collins1, H Zhao, R B Womer, F G Barr. 1. Department of Pathology, Children's Hospital of Philadelphia, Philadelphia, PA, USA. COLV5Q@CHMCC.ORG
Abstract
BACKGROUND: Most alveolar rhabdomyosarcomas (ARMS) have chromosome translocations and resultant gene fusion products. The more common translocation fuses the PAX3 and FKHR genes; patients who have PAX3-FKHR-positive ARMS have reduced event-free survival compared to patients with ARMS containing the less common translocation that fuses the PAX7 and FKHR genes. PROCEDURE: We examined histology, immunohistochemical markers of differentiation, and cell cycle characteristics of a panel of ARMS containing either PAX3-FKHR or PAX7-FKHR transcript to determine if these features differ between the ARMS subsets. RESULTS: Cell cycle parameters varied significantly: the number of nuclei that stained with either an immunohistochemical marker of proliferation (MIB1), or a TUNEL-based assay for apoptosis was significantly greater in tumors that expressed PAX3-FKHR compared to tumors that expressed PAX7-FKHR transcript. CONCLUSIONS: We conclude that compared to PAX7-FKHR-containing tumors, ARMS that contain PAX3-FKHR transcript have (1) increased cell proliferation, consistent with greater loss of cell cycle regulation, and (2) apoptosis that is increased but insufficient to prevent tumor formation. More marked cell cycle dysregulation may contribute to poorer prognosis for patients with ARMS that have PAX3-FKHR fusion. Med Pediatr Oncol 2001;37:83-89. Copyright 2001 Wiley-Liss, Inc.
BACKGROUND: Most alveolar rhabdomyosarcomas (ARMS) have chromosome translocations and resultant gene fusion products. The more common translocation fuses the PAX3 and FKHR genes; patients who have PAX3-FKHR-positive ARMS have reduced event-free survival compared to patients with ARMS containing the less common translocation that fuses the PAX7 and FKHR genes. PROCEDURE: We examined histology, immunohistochemical markers of differentiation, and cell cycle characteristics of a panel of ARMS containing either PAX3-FKHR or PAX7-FKHR transcript to determine if these features differ between the ARMS subsets. RESULTS: Cell cycle parameters varied significantly: the number of nuclei that stained with either an immunohistochemical marker of proliferation (MIB1), or a TUNEL-based assay for apoptosis was significantly greater in tumors that expressed PAX3-FKHR compared to tumors that expressed PAX7-FKHR transcript. CONCLUSIONS: We conclude that compared to PAX7-FKHR-containing tumors, ARMS that contain PAX3-FKHR transcript have (1) increased cell proliferation, consistent with greater loss of cell cycle regulation, and (2) apoptosis that is increased but insufficient to prevent tumor formation. More marked cell cycle dysregulation may contribute to poorer prognosis for patients with ARMS that have PAX3-FKHR fusion. Med Pediatr Oncol 2001;37:83-89. Copyright 2001 Wiley-Liss, Inc.
Authors: Maciej Tarnowski; Katarzyna Grymula; Rui Liu; Joanna Tarnowska; Justyna Drukala; Janina Ratajczak; Robert A Mitchell; Mariusz Z Ratajczak; Magda Kucia Journal: Mol Cancer Res Date: 2010-09-22 Impact factor: 5.852
Authors: Gabriela Schneider; Ewa Bryndza; Ahmed Abdel-Latif; Janina Ratajczak; Magdalena Maj; Maciej Tarnowski; Yuri M Klyachkin; Peter Houghton; Andrew J Morris; Axel Vater; Sven Klussmann; Magdalena Kucia; Mariusz Z Ratajczak Journal: Mol Cancer Res Date: 2013-04-24 Impact factor: 5.852
Authors: Gabriela Schneider; Zachariah Payne Sellers; Ahmed Abdel-Latif; Andrew J Morris; Mariusz Z Ratajczak Journal: Mol Cancer Res Date: 2014-07-17 Impact factor: 5.852
Authors: Maciej Tarnowski; Katarzyna Grymula; Ryan Reca; Kacper Jankowski; Radoslaw Maksym; Joanna Tarnowska; Grzegorz Przybylski; Frederic G Barr; Magdalena Kucia; Mariusz Z Ratajczak Journal: Mol Cancer Res Date: 2010-01-12 Impact factor: 5.852